Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Short term Debt (2018 - 2022)

Historic Short term Debt for Lipocine (LPCN) over the last 5 years, with Q1 2022 value amounting to $1.5 million.

  • Lipocine's Short term Debt fell 5553.5% to $1.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.5 million, marking a year-over-year decrease of 5553.5%. This contributed to the annual value of $2.3 million for FY2021, which is 3067.52% down from last year.
  • Latest data reveals that Lipocine reported Short term Debt of $1.5 million as of Q1 2022, which was down 5553.5% from $2.3 million recorded in Q4 2021.
  • In the past 5 years, Lipocine's Short term Debt registered a high of $4.0 million during Q2 2021, and its lowest value of $1.3 million during Q1 2018.
  • Moreover, its 5-year median value for Short term Debt was $3.2 million (2020), whereas its average is $2.7 million.
  • In the last 5 years, Lipocine's Short term Debt soared by 14866.08% in 2019 and then plummeted by 5553.5% in 2022.
  • Over the past 5 years, Lipocine's Short term Debt (Quarter) stood at $3.3 million in 2018, then changed by 0.0% to $3.3 million in 2019, then changed by 0.0% to $3.3 million in 2020, then plummeted by 30.68% to $2.3 million in 2021, then crashed by 35.86% to $1.5 million in 2022.
  • Its Short term Debt was $1.5 million in Q1 2022, compared to $2.3 million in Q4 2021 and $3.1 million in Q3 2021.